Literature DB >> 29311399

Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease.

Nazarii Kobyliak1, Ludovico Abenavoli2, Tetyana Falalyeyeva3, Tetyana Beregova3.   

Abstract

INTRODUCTION AND AIM: Today probiotics have been suggested as a treatment for the prevention of non-alcoholic fatty liver disease (NAFLD). Smectite is a natural silicate that binds to digestive mucous and has the ability to bind endo- and exotoxins. The present study was designed to determine whether probiotics plus smectite is superior to probiotic alone on the monosodium glutamate (MSG) induced NAFLD model in rats.
MATERIALS AND METHODS: We included 60 rats divided into 4 groups 15 animals in each. Rats of group I were intact. Newborns rats of groups II-IV were injected with MSG. The III (Symbiter) group received 2.5 ml/kg of multiprobiotic "Symbiter" containing concentrated biomass of 14 probiotic bacteria genera. The IV (Symbiter+Smectite) groups received "Symbiter Forte" combination of probiotic biomass with smectite gel (250 mg).
RESULTS: In both interventional groups reduction of total NAS score as compared to MSG-obesity was observed. Indeed similar values of steatosis score (0.93 ± 0.22 vs. 0.87 ± 0.16) in both treatment groups, we observed that lower total score for Symbiter+ Smectite are associated with more pronounced reduction of lobular inflammation (0.13 ± 0.09 vs. 0.33 ± 0.15) as compared to administration of probiotic alone. This data accompanied with significant reduction of IL-1 and restoration of IL-10 between these 2 groups.
CONCLUSIONS: Additional to alive probiotic administration of smectite gel due to his absorbent activity and mucus layer stabilization properties can impact on synergistic enhancement of single effect which manifested with reduction of lobular inflammation and at list partly steatohepatitis prevention.

Entities:  

Keywords:  Diosmectite. Nutraceuticals. Non-alcoholic steatohepatitis. Obesity. Prevention.

Mesh:

Substances:

Year:  2018        PMID: 29311399     DOI: 10.5604/01.3001.0010.7547

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  6 in total

1.  Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.

Authors:  Minmin Luo; Junbin Yan; Liyan Wu; Jinting Wu; Zheng Chen; Jianping Jiang; Zhiyun Chen; Beihui He
Journal:  J Immunol Res       Date:  2021-08-17       Impact factor: 4.818

2.  New insights on strain-specific impacts of probiotics on insulin resistance: evidence from animal study.

Authors:  Nazarii Kobyliak; Tetyana Falalyeyeva; Olena Tsyryuk; Majid Eslami; Dmytro Kyriienko; Tetyana Beregova; Liudmila Ostapchenko
Journal:  J Diabetes Metab Disord       Date:  2020-02-16

3.  Probiotic Composition and Chondroitin Sulfate Regulate TLR-2/4-Mediated NF-κB Inflammatory Pathway and Cartilage Metabolism in Experimental Osteoarthritis.

Authors:  Oleksandr Korotkyi; Alevtina Huet; Kateryna Dvorshchenko; Nazarii Kobyliak; Tetyana Falalyeyeva; Liudmyla Ostapchenko
Journal:  Probiotics Antimicrob Proteins       Date:  2021-01-18       Impact factor: 4.609

Review 4.  Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Ludovico Abenavoli; Tetyana Falalyeyeva; Luigi Boccuto; Olena Tsyryuk; Nazarii Kobyliak
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-11

Review 5.  The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults.

Authors:  Carmen Alonso-Cotoner; Mar Abril-Gil; Mercé Albert-Bayo; John-P Ganda Mall; Elba Expósito; Ana M González-Castro; Beatriz Lobo; Javier Santos
Journal:  Adv Ther       Date:  2021-03-18       Impact factor: 3.845

6.  Lactobacillus johnsonii BS15 combined with abdominal massage on intestinal permeability in rats with nonalcoholic fatty liver and cell biofilm repair.

Authors:  Wei Zhang; Huanan Li; Na Zhao; Xiongfei Luo; Siwen Liu; An Bao; Yingying Chen; Haiteng Wang; Junshi Wang; Jingui Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.